TRIPS WAIVER
Reto M. Hilty et al, Covid 19 and the Role of Intellectual Property: Position Statement of the Max Planck Institute for Innovation and Competition https://www.ip.mpg.de/en/nc/research/research-news/covid-19-and-the-role-of-intellectual-property.html
Max Planck Institute’s Reaction
1. Waiving IP rights will not scale or speed up vaccine manufacturing and distribution.
2. IP rights are the basis for collaborations and contracts.
3. A waiver of IP rights will not waive regulatory requirements for vaccine authorisation.
4. It is questionable whether a waiver of IP rights will significantly reduce prices for vaccines.
5. The TRIPS Agreement contains sufficient flexibilities to prevent negative effects of patents.
6. A comprehensive waiver of IP rights will likely have a detrimental effect on incentives for drug innovation.
7. Concerns regarding profit maximisation by IP holders is not a valid reason for a waiver of IP rights.
8. Accountability for the use of public funds invested in vaccine development requires transparency.
9. The scope of the waiver is not clear.
10. Global governance could provide better support to developing countries.
https://www.bio.org/press-release/support-trips-waiver-sets-dangerous-precedent
BIO strongly encourages the Administration to:
A Prevent the expropriation of technology that has use beyond COVID vaccines which could be used to compete against American companies and workers in the future;
B Protect American companies from the coerced transfer of technology by foreign governments;
C Ensure that these actions do not impede global supply chains for existing facilities;
D Avoid any precedents that would work to undermine incentives to develop vaccines and treatments in future pandemics; and
E Ensure that the manufacturing of any vaccines is done in compliance with rigorous safety and manufacturing standards.
USTR声明に対する反応
以下は当方も企画執筆にかかわりました。
https://aippi.org/wp-content/uploads/2021/05/AIPPI-Position-Paper-on-WTO-Waiver_12May2021.pdf
この記事が気に入ったらサポートをしてみませんか？